GSK-070
- Generic Name
- GSK-070
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
Phase 2
Recruiting
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- University College, London
- Target Recruit Count
- 2500
- Registration Number
- NCT06114628
- Locations
- πΏπ¦
TASK Eden, George, South Africa
πΉπΏNIMR Mbeya, Mbeya, Tanzania
πΏπ¦TASK Brooklyn, Cape Town, South Africa
Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis
Phase 2
Recruiting
- Conditions
- Tuberculosis
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 128
- Registration Number
- NCT05382312
- Locations
- πΏπ¦
GSK Investigational Site, Cape Town, South Africa
An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 76
- Registration Number
- NCT03557281
- Locations
- πΏπ¦
GSK Investigational Site, Cape Town, South Africa
First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy Subjects
- First Posted Date
- 2017-03-09
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT03075410
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath